GlaxoSmithKline has paid £146 million for Basilea Pharmaceutica’s dermatology drug Toctino. Toctino (alitretinoin) is approved for the treatment of adults …
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion

